IAPS Roc'd PCT/PTO 23 JAN 2006

SEQUENCE LISTING

Corresponding to PCT/CN2004/000842

序列表

<110>	中国	国医学科学院	医药生物技术	术所						
<120>	有抑制血管生成及抗肿瘤作用的强化融合蛋白 Fv-LDP-AE 及其用途									
<130>	IECO30032PCT									
<160>	6									
<170>	PatentIn version 3.1									
<210>	1									
<211>	1119	9								
	DNA									
<213>	art	ifical								
<400>	1									
atgcagg	gtga	agctgcagca	gtctggaact	gaagtggtaa	agcctggggc	ttcagtgaag	60			
ttgtcct	tgca	aggcttctgg	ctacatcttc	acaagttatg	atatagactg	ggtgaggcag	120			
acgcctg	gaac	agggacttga	gtggattgga	tggatttttc	ctggagaggg	gagtactgaa	180			
tacaatg	gaga	agttcaaggg	cagggccaca	ctgagtgtag	acaagtcctc	cagcacagcc	240			
tatatgg	gagc	tcactaggct	gacatctgag	gactctgctg	tctatttctg	tgctagaggg	300			
gactact	ata	ggcgctactt	tgacttgtgg	ggccaaggga	ccacggtcac	cgtctcctca	360			
ggtggag	gcg	gttcaggcgg	aggtggctct	ggcggtggcg	gatcggacat	cgagctcact	420			
cagtctc	cag	cttctttggc	tgtgtctcta	gggcagaggg	ccaccatatc	ctgcagagcc	480			
agtgaaa	gtg	ttgatactta	tggcgatact	tttatgtact	ggtaccagca	gaaaccagga	540			
cagocac	cca	aactcctcat	ctatcttgca	accaacctag	gatctggggt	ccctgccagg	600			
ttcagtg	gca	gtgggtctag	gacaaacttc	accctcacca	ttgatcctgt	ggaggctgat	660			
gatgctg	caa	cctattactg	tcagcaaaat	aatgaggatc	cgtacacgtt	cggagggggc	720			
accaagc	tgg.	aaatcaaacg	tggtggaggc	ggttcaccat	gggcgcccgc	cttctccgtc	780			

agtcccgcct	cgggtctgag	tgacggacag	agcgtgtcgg	tgtcggtcag	cggtgccgcc	840
gccggcgaga	cctactacat	cgcccagtgc	gctccggtcg	gtggccagga	cgcgtgcaac	900
ccggcgaccg	cgacgtcctt	caccacggac	gcgtccggag	cggcgtcgtt	cagcttcgtc	960
gtgcgcaagt	cgtacacggg	ctccacgccc	gaaggcacgc	cggtcggcag	cgtcgactgc	1020
gccacggccg	cctgtaacct	cggcgccggc	aactccgggc	tcgacctcgg	ccacgtggct	1080
ctgaccttcg	gcctcgagca	ccaccaccac	caccactga			1119

<210> 2

<211> 372

<212> PRT

<213> artifical

<400> 2

Met Gln Val Lys Leu Gln Gln Ser Gly Thr Glu Val Val Lys Pro Gly
1 5 10 15

Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser 20 25 30

Tyr Asp Ile Asp Trp Val Arg Gln Thr Pro Glu Gln Gly Leu Glu Trp 35 40 45

Ile Gly Trp Ile Phe Pro Gly Glu Gly Ser Thr Glu Tyr Asn Glu Lys 50 55 60

Phe Lys Gly Arg Ala Thr Leu Ser Val Asp Lys Ser Ser Ser Thr Ala 65 70 75 80

Tyr Met Glu Leu Thr Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe 85 90 95

Cys Ala Arg Gly Asp Tyr Tyr Arg Arg Tyr Phe Asp Leu Trp Gly Gln
100 105 110

Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 115 120 125

Gly Ser Asp Ile Glu Leu Ser Gly Gly Gly Gly Thr Gln Ser Pro Ala 130 135 140

Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala 145 150 155 160

Ser Glu Ser Val Asp Thr Tyr Gly Asp Thr Phe Met Tyr Trp Tyr Gln 165 170 175

Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Thr Asn 180 185 190

Leu Gly Ser Gly Val Pro Ala Gly Phe Ser Gly Ser Gly Ser Arg Thr 195 200 205

Asn Phe Thr Leu Thr Ile Asp Pro Val Glu Ala Asp Asp Ala Ala Thr 210 215 220

Tyr Tyr Cys Gln Gln Asn Asn Glu Asp Pro Tyr Thr Phe Gly Gly Gly 225 230 235 240

Thr Lys Leu Glu Ile Lys Arg Gly Gly Gly Gly Ser Glu Phe Ala Pro 245 250 255

Ala Phe Ser Val Ser Pro Ala Ser Gly Leu Ser Asp Gly Gln Ser Val 260 265 270

Ser Val Ser Val Ser Gly Ala Ala Gly Glu Thr Tyr Tyr Ile Ala 275 280 285

Gln Cys Ala Pro Val Gly Gln Asp Ala Cys Asn Pro Ala Thr Ala 290 295 300

Thr Ser Phe Thr Thr Asp Ala Ser Gly Ala Ala Ser Phe Ser Phe Val 305 310 315 320

Val Arg Lys Ser Tyr Thr Gly Ser Thr Pro Glu Gly Thr Pro Val Gly 325 330 335

Ser Val Asp Cys Ala Thr Ala Ala Cys Asn Leu Gly Ala Gly Asn Ser 340 . 345 350

Gly Leu Asp Leu Gly His Val Ala Leu Thr Phe Gly Leu Glu His His 355 360 365

His His His His 370

<210> 3

<211> 29

<212> DNA

<213> artifical

<400> 3

cgcatatgca ggtgaagctg cagcagtct

29

<210> 4

<211> 38

<212> DNA

<213> artifical

<400> 4

cggaattctg aaccgcctcc accacgtttg atttccag

38

<210> 5

<211> 32

<212> DNA

<213> artifical

<400> 5

cggaattcgc gcccgccttc tccgtcagtc cc

32

<210> 6

<211> 33

<212> DNA

<213> artifical

<400> 6

ccgctcgagt cagccgaagg tcagagccac gtg

33